抗PD-1联合干扰素α治疗后儿童多内分泌自身免疫与糖尿病酮症酸中毒
本文报告一例儿童纤维板层型肝细胞癌患者在抗PD-1和干扰素α治疗期间出现新发自身免疫性糖尿病及糖尿病酮症酸中毒,与自发1型糖尿病不同,该患者进展迅速且β细胞自身抗体阴性,同时21-羟化酶自身抗体阳性提示合并肾上腺自身免疫。作者指出成人免疫相关不良事件管理指南可能不适用于儿童。
要点
- 儿童ICI治疗中可出现新发自身免疫性糖尿病并快速进展为糖尿病酮症酸中毒。
- 该例β细胞自身抗体阴性但21-羟化酶自身抗体阳性,提示多内分泌自身免疫。
- 成人IRAEs管理指南可能不适用于儿童,需考虑发育背景下的自身免疫风险差异。
核心结论
- 儿童在接受抗PD-1和干扰素α治疗期间可出现新发自身免疫性糖尿病及糖尿病酮症酸中毒,且表现与自发1型糖尿病不同。
- 成人IRAEs管理指南可能不适用于儿童患者。
研究设计与样本
- 单例病例报告,对象为接受ICI治疗纤维板层型肝细胞癌的儿童患者。
主要发现
- 患者在ICI治疗期间出现新发自身免疫性糖尿病和糖尿病酮症酸中毒。
- 该患者糖尿病进展迅速且已知β细胞自身抗体阴性,与自发1型糖尿病不同。
- 患者21-羟化酶自身抗体阳性,提示合并肾上腺自身免疫。
临床怎么用
- 儿童ICI治疗期间需警惕新发自身免疫性糖尿病及糖尿病酮症酸中毒,并注意筛查多内分泌自身免疫。
- 儿童IRAEs管理不能直接照搬成人指南,需结合发育背景评估自身免疫风险。
局限性
- 仅为单例病例报告,无法确定儿童IRAEs的发生率、表现谱和病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitor (ICI) therapies are now first-line therapy for many advanced malignancies in adults, with emerging use in children. With increasing ICI use, prompt recognition and optimal management of ICI-associated immune-related adverse events (IRAEs) are critical. Nearly 60% of ICI-treated adults develop IRAEs, which commonly manifest as autoimmune skin, gastrointestinal, and endocrine disease and can be life-threatening. The incidence, presentation, and disease course of spontaneous autoimmune diseases differ between adults and children, but the pattern of pediatric IRAEs is currently unclear. We report a case of a pediatric patient presenting with new onset autoimmune diabetes mellitus and diabetic ketoacidosis during ICI treatment of fibrolamellar hepatocellular carcinoma (FLC). Distinct from spontaneous type 1 diabetes mellitus (T1DM), this patient progressed rapidly and was negative for known β cell autoantibodies. Additionally, the patient was positive for 21-hydroxylase autoantibodies, suggesting development of concomitant adrenal autoimmunity. Current guidelines for the management of IRAEs in adults may not be appropriate for the management of pediatric patients, who may have different autoimmune risks in a developmental context.
引用
- Dasgupta A, Tsay E, Federman N, et al. Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α. Pediatrics. 2022. PMID: 35274131. doi:10.1542/peds.2021-053363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。